Glucocorticoid-driven gene expression in circulating monocytes and neutrophils in health and severe inflammation - Molendijk, Arthur; Koenderman, Leo (medRxiv, 2024)
Glucocorticoids (GCs) are used as anti-inflammatory and immunosuppressive drugs in many immune mediated diseases, but their use in sepsis and shock is controversial. This is caused in part by a lack of information regarding the responding cell types and GC-regulated genes in vivo. We used public blood transcriptomic datasets and GC-induced query genes to obtain 2 robust gene expression correlation signatures of GC induction, either in the absence or in the presence of severe inflammation. GC signature 1 originated from circadian cortisol with biases for gene expression in NK cells and neutrophils. GC signature 2 originated from GC in severe inflammation, mainly with biases for gene expression in monocytes and neutrophils. Many genes upregulated by GC treatment in septic shock and burn shock were also present as high-ranking genes in GC signatures, which pointed to their direct regulation by GC. Robust GC signatures were also obtained from dataset collections of monocytes and neutrophils, separately, and predicted cellular effects. Additionally, gene induction by GC was put into a wider framework of gene expression in circulating monocytes and neutrophils in health and systemic inflammation. We present and interpret a large number of GC-regulated genes in different blood cells and tissues, and select 2 whole blood transcriptomic biomarker gene sets, GC-1 and GC-2, for monitoring cortisol action in health, and in severe inflammation, respectively. GC signature 2 was found in sepsis and many other inflammatory diseases, both from treatment with GC, and from endogenous GC.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://www.umcutrecht.nl https://github.com/ArthurJohannes/GCblood_repo Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used only openly available human data located at NCBI GEO database, and at the ArrayExpress repositoryI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors https://www.umcutrecht.nl https://www.ncbi.nlm.nih.gov/gds https://www.ebi.ac.uk/biostudies/arrayexpress https://github.com/ArthurJohannes/GCblood_repo